Fig. 5From: The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitationFive-year survival of patients expressing high CD45RO/ICOS vs low CD45RO/ICOS in the validation cohort. Cases falling into the high group are represented by the red line with the blue line representing low expressionBack to article page